Management of antibiotic resistance in the intensive care unit setting

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 3, 2010, Pages 289-302

  Petrosillo, Nicola ^a   Capone, Alessandro ^a   Di Bella, Stefano ^a   Taglietti, Fabrizio ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Antimicrobial combination therapy; Antimicrobial resistance; Antimicrobial stewardship program; De escalation therapy; Intensive care; Severe infections; Vancomycin minimal inhibitory concentration

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; BETA LACTAM ANTIBIOTIC; BIAPENEM; CARBAPENEM; CIPROFLOXACIN; DORIPENEM; IMIPENEM; LINEZOLID; MEROPENEM; METICILLIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL COLONIZATION; CRITICAL ILLNESS; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG TREATMENT FAILURE; ENTEROBACTERIACEAE; ENTEROCOCCUS; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; HOSPITAL ADMISSION; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PNEUMONIA; PSEUDOMONAS AERUGINOSA; REVIEW; SEPSIS; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS;

EID: 77749279581     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.7     Document Type: Review

References (125)

1. Vincent JL, Sakr Y, Sprung CL et al.; Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit. Care Med. 34, 344-353 (2006).
2. Alberti C, Brun-Buisson C, Burchardi H et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 28, 108-121 (2002).
3. Fridkin SK, Welbel SF, Weinstein RA. Magnitude and prevention of nosocomial infections in the intensive care unit. Infect. Dis. Clin. North Am. 11, 479-496 (1997).
4. Wroblewska MM, Rudnicka J, Marchel H, Luczak M. Multidrug-resistant bacteria isolated from patients hospitalised in intensive care units. Int. J. Antimicrob. Agents 27, 285-289 (2006).
5. Gastmeier P, Sohr D, Geffers C, Behnke M, Rüden H. Risk factors for death due to nosocomial infection in intensive care unit patients: findings from the Krankenhaus Infektions Surveillance System. Infect. Control Hosp. Epidemiol 28, 466-472 (2007).
6. Damas P, Ledoux D, Nys M et al. Intensive care unit acquired infection and organ failure. Intensive Care Med. 34, 856-864 (2008).
7. Brun-Buisson C. ICU-acquired infections and sepsis: more of a deadly duo. Intensive Care Med. 34, 793-795 (2008).
8. Fridkin SK, Steward CD, Edwards JR et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE Phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin. Infect. Dis. 29, 245-252 (1999).
9. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 32, 470-485 (2004).
10. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R; National Nosocomial Infections Surveillance System. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin. Infect. Dis. 42, 389-391 (2006).
11. Gaynes R, Edwards JR; National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by Gram-negative bacilli. Clin. Infect. Dis. 41, 848-854 (2005).
12. Lockhart SR, Abramson MA, Beekmann SE et al. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J. Clin. Microbiol. 45, 3352-3359 (2007).
13. Cantón R, Novais A, Valverde A et al. Prevalence and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 14(Suppl. 1), S144-S153 (2008).
14. Rice LB. The clinical consequences of antimicrobial resistance. Curr. Opin. Microbiol. 12, 476-481 (2009).
15. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill. 13(47), ii, 19045 (2008).
16. Gholizadeh Y, Courvalin P. Acquired and intrinsic glycopeptide resistance in enterococci. Int. J. Antimicrob. Agents. 16(Suppl. 1), S11-S17 (2000).
17. Fish DN, Ohlinger MJ. Antimicrobial resistance: factors and outcomes. Crit. Care Clin. 22, 291-311 (2006).
18. Barsanti MC, Woeltje KF. Infection prevention in the intensive care unit. Infect. Dis. Clin. North Am. 23, 703-725 (2009).
19. Hidron AI, Edwards JR, Patel J et al.; National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007 Infect. Control Hosp. Epidemiol. 29, 996-1011 (2008).
20. NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am. J. Infect. Control 31, 481-498 (2003).
21. Thompson DS, Workman R, Strutt M. Decline in the rates of methicillin-resistant Staphylococcus aureus acquisition and bacteraemia in a general intensive care unit between 1996 and 2008. J. Hosp. Infect. 71, 314-319 (2009).
22. Burton DC, Edwards JR, Horan TC, Jernigan JA, Fridkin SK. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007 JAMA 301, 727-736 (2009).
23. Pagani L, Falciani M, Aschbacher R. Use of microbiologic findings to manage antimicrobials in the intensive care unit. Infect. Control Hosp. Epidemiol. 30, 309-311 (2009).
24. Theaker C, Ormond-Walsh S, Azadian B, Soni N. MRSA in the critically ill. J. Hosp. Infect. 48, 98-102 (2001).
25. Niven DJ, Laupland KB, Gregson DB, Church DL. The S. aureus screening initiative group. Epidemiology of Staphylococcus aureus nasal colonization and influence on outcome in the critically ill. J. Crit. Care 24(4), 583-589 (2009).
26. Barbarini D, Fumagalli P, Marone P. Methicillin-resistant S. aureus (MRSA) in an intensive care unit: a one year survey. Infez. Med. 9, 237-245 (2001).
27. Tacconelli E, De Angelis G, Cataldo MA et al. Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob. Agents Chemother. 53, 4264-4269 (2009).
28. Bloemendaal AL, Fluit AC, Jansen WM et al. Acquisition and cross-transmission of Staphylococcus aureus in European intensive care units. Infect. Control Hosp. Epidemiol 30, 117-124 (2009).
29. Mayhall CG. Methicillin-resistant Staphylococcus aureus/ vancomycin-resistant Enterococci colonization and infection in the critical care unit. In: Infectious Diseases in Critical Care Medicine (2nd Edition). Cunha BA (Ed.). Informa Healthcare, NY, USA (2007).
30. Thompson DS. Methicillin-resistant Staphylococcus aureus in a general intensive care unit. J. R. Soc. Med. 97, 521-526 (2004).
31. Von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study group. N. Engl. J. Med. 344, 11-16 (2001).
32. Tacconelli E, De Angelis G, Cataldo MA et al. Usage of carbapenems significantly increase the rate of new colonisation due to antibiotic-resistant bacteria in hospitalized patients. Presented at: 18th European Congress of Clinical Microbiology and Infectious Diseases. Barcelona, Spain, 19-22 April 2008 (Abstract O395).
33. Fridkin SK, Edwards JR, Courval JM et al. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project and the National Nosocomial Infections Surveillance (NNIS) System Hospitals. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann. Intern. Med. 135, 175-183 (2001).
34. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomyin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn. Microbiol. Infect. Dis. 58, 163-170 (2007).
35. Streit JM, Jones RN, Sader HS, Fritshe TR. Assessment of pathogen occurrences and resistance profiles among infected patients in intensive care unit: report from the SENTRY Antimicrobial Surveillance Program. Int. J. Antimicrob. Agents 24, 111-118 (2004).
36. Zirakzadeh A, Patel R. Vancomycin-resistant enterococci: colonization, infection, detection and treatment. Mayo Clin. Proc. 81, 529-536 (2006).
37. Leclercq R. Epidemiological and resistance issues in multidrug-resistant staphylococci and enetrococci. Clin. Microbiol. Infect. 15, 224-231 (2009).
38. Gould IM. The epidemiology of antibiotic resistance. Int. J. Antimicrob. Agents 32(Suppl. 1), S2-S9 (2008).
39. Bryant S, Wilbeck J. Vancomycin-resistant enterococcus in critical care areas. Crit. Care Nurs. Clin. North Am. 19, 69-75 (2007).
40. Burrell LJ, Grabsch EA, Padiglione AA, Grayson ML. Prevalence of colonisation with vancomycin-resistant enterococci (VRE) among haemodyalisis outpatients in Victoria: implications for screening. Med. J. Aus. 182, 492 (2005).
41. Zhanel GG, DeCorby M, Laing N et al. Canadian Antimicrobial Resistance Alliance (CARA). Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob. Agents Chemother. 52, 1430-1437 (2008).
42. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J. Antimicrob. Chemother. 59, 165-174 (2007).
43. Rodríguez-Baño J, Navarro MD, Romero L et al. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in nonhospitalized patients. J. Clin. Microbiol. 42, 1089-1094 (2004).
44. March A, Aschbacher R, Dhanji H et al. Colonization of residents and staff of a long-term-care facility and adjacent acute-care hospital geriatric unit by multiresistant bacteria. Clin. Microbiol. Infect. DOI: 10.1111/j.1469-0691. 2009.03024.x (2009) (Epub ahead of print).
45. Meyer E, Gastmeier P, Schwab F. The burden of multiresistant bacteria in German intensive care units. J. Antimicrob. Chemother. 62, 1474-1476 (2008).
46. Jean SS, Hsueh PR, Lee WS et al. Nationwide surveillance of antimicrobial resistance among non-fermentative Gram-negative bacteria in intensive care units in Taiwan: SMART programme data 2005. Int. J. Antimicrob. Agents 33, 266-271 (2009).
47. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N. Engl. J. Med. 358, 1271-1281 (2008).
48. Berg DE, Hershow RC, Ramirez CA, Weinstein RA. Control of nosocomial infections in an intensive care unit in Guatemala City. Clin. Infect. Dis. 21, 588-593 (1995).
49. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51, 3471-3484 (2007).
50. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis. 46, 1254-1263 (2008).
51. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289, 885-888 (2003).
52. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob. Agents Chemother. 47, 1681-1688 (2003).
53. Flamm RK, Weaver MK, Thornsberry C, Jones ME, Karlowsky JA, Sahm DF. Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob. Agents Chemother. 48, 2431-2436 (2004).
54. Mendes C, Oplustil C, Sakagami E, Turner P, Kiffer C; MYSTIC Brazil Group. Antimicrobial susceptibility in intensive care units: MYSTIC Program Brazil 2002. Braz. J. Infect. Dis. 9, 44-51 (2005).
55. Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob. Agents Chemother. 48, 4606-4610 (2004).
56. Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit - a European and North American Surveillance study (2000-2002). Ann. Clin. Microbiol. Antimicrob. 3, 14 (2004).
57. Furtado GH, Martins ST, Machado AM, Wey SB, Medeiros EA. Clinical culture surveillance of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter species in a teaching hospital in Sao Paulo, Brazil: a 7-year study. Infect. Control Hosp. Epidemiol. 27, 1270-1273 (2006).
58. Hanberger H, Arman D, Gill H et al. Surveillance of microbial resistance in European Intensive Care Units: a first report from the Care-ICU programme for improved infection control. Intensive Care Med. 35, 91-100 (2009).
59. Miranda MC, Pérez F, Zuluaga T et al. Grupo de Resistencia Bacteriana Nosocomial de Colombia. [Antimicrobial resistance in Gram Negative bacteria isolated from intensive care units of Colombian hospitals, WHONET 2003, 2004 and 2005]. Biomedica 26, 424-433 (2006).
60. Varaiya A, Kulkarni N, Kulkarni M, Bhalekar P, Dogra J. Incidence of metallo β lactamase producing Pseudomonas aeruginosa in ICU patients. Indian J. Med. Res. 127, 398-402 (2008).
61. Lee CY, Chen PY, Huang FL, Lin CF. Microbiologic spectrum and susceptibility pattern of clinical isolates from the pediatric intensive care unit in a single medical center - 6 years' experience. J. Microbiol. Immunol. Infect. 42, 160-165 (2009).
62. Hsu LY, Tan TY, Jureen R et al. Antimicrobial drug resistance in Singapore hospitals. Emerg. Infect. Dis. 13, 1944-1947 (2007).
63. Patzer JA, Dzierzanowska D, Turner PJ. Trends in antimicrobial susceptibility of Gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007). J. Antimicrob. Chemother. 62, 369-375 (2008).
64. Madani N, Rosenthal VD, Dendane T, Abidi K, Zeggwagh AA, Abouqal R. Health-care associated infections rates, length of stay, and bacterial resistance in an intensive care unit of Morocco: findings of the International Nosocomial Infection Control Consortium (INICC). Int. Arch. Med. 2, 29 (2009).
65. Merrer J, Santoli F, Appéré de Vecchi C, Tran B, De Jonghe B, Outin H. "Colonization pressure" and risk of acquisition of methicillin-resistant Staphylococcus aureus in a medical intensive care unit. Infect. Control Hosp. Epidemiol. 21, 718-723 (2000).
66. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in health care settings, 2006. Am. J. Infect. Control. 35(10 Suppl. 2), S165-S193 (2007).
67. Bhalla A, Pultz NJ, Gries DM et al. Acquisition of nosocomial pathogens on hands after contact with environmental surfaces near hospitalized patients. Infect. Control Hosp. Epidemiol. 25, 164-167 (2004).
68. Pittet D, Allegranzi B, Boyce J; World Health Organization World Alliance for Patient Safety First Global Patient Safety Challenge Core Group of Experts. The World Health Organization Guidelines on Hand Hygiene in Health Care and their consensus recommendations. Infect. Control Hosp. Epidemiol. 30, 611-622 (2009).
69. Popovich KJ, Hota B, Hayes R, Weinstein RA, Hayden MK. Effectiveness of routine patient cleansing with chlorhexidine gluconate for infection prevention in the medical intensive care unit. Infect. Control Hosp. Epidemiol. 30, 959-963 (2009).
70. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42, 657-668 (2006).
71. Bassetti M, Cruciani M, Righi E et al. Antimicrobial use and resistance among Gram-negative bacilli in an Italian intensive care unit (ICU). J. Chemother. 18, 261-267 (2006).
72. Tsai HT, Wang JT, Chen CJ, Chang SC. Association between antibiotic usage and subsequent colonization or infection of extensive drug-resistant Acinetobacter baumannii: a matched case - control study in intensive care units. Diagn. Microbiol. Infect. Dis. 62, 298-305 (2008).
73. Ibrahim EH, Tracy L, Hill C, Fraser VJ, Kollef MH. The occurrence of ventilator-associated pneumonia in a community hospital: risk factors and clinical outcomes. Chest 120, 555-561 (2001).
74. Chastre J. Ventilator-associated pneumonia: what is new? Surg. Infect. (Larchmt). 7(Suppl. 2), S81-S85 (2006).
75. Chastre J, Wolff M, Fagon JY et al. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290, 2588-2598 (2003).
76. Grammatikos AP, Siempos II, Michalopoulos A, Falagas ME. Optimal duration of the antimicrobial treatment of ventilator-acquired pneumonia. Expert Rev. Anti Infect. Ther. 6, 861-866 (2008).
77. Hedrick TL, McElearney ST, Smith RL, Evans HL, Pruett TL, Sawyer RG. Duration of antibiotic therapy for ventilator-associated pneumonia caused by non-fermentative Gram-negative bacilli. Surg. Infect. (Larchmt). 8, 589-597 (2007).
78. Hoffken G, Niederman MS. Nosocomial pneumonia: the importance of a deescalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 122, 2183-2196 (2002).
79. Kollef MH, Sherman G, Ward S, Fraser V Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115, 462-474 (1999)
80. Luna CM, Vujacich P, Niederman MS et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111, 676-685 (1997).
81. Tellado JM, Sen SS, Caloto MT, Kumar RN, Nocea G. Consequences of inappropriate initial empiric parenteral antibiotic therapy among patients with community-acquired intra-abdominal infections in Spain. Scand. J. Infect. Dis. 39, 947-955 (2007).
82. Tumbarello M, Sali M, Trecarichi EM et al. Bloodstream infections caused by extended-spectrum-β-lactamase-producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob. Agents Chem. 52, 3244-3252 (2008).
83. MacDougall C, Polk RE. Antimicrobial stewardship programs in healthcare systems. Clin. Microbiol. Rev. 18, 638-656 (2005).
84. Lesprit P, Brun-Buisson C. Hospital antibiotic stewardship. Curr. Opin. Infect. Dis. 21, 344-349 (2008).
85. Owens RC. Antimicrobial stewardship: application in the intensive care. Infect. Dis. Clin. N. Am. 23, 683-702 (2009).
86. Lawrence KL, Kollef MH. Antimicrobial stewardship in the intensive care unit. Advances and obstacles. Am. J. Respir. Crit. Care. Med. 179, 434-438 (2009).
87. Thursky KA, Buising KL, Bak N et al. Reduction of broad-spectrum antibiotic use with computerized decision support in an intensive care unit. Int. J. Qual. Health Care 18, 224-231 (2006).
88. Thiel SW, Asghar MF, Micek ST, Reichley RM, Doherty JA, Kollef MH. Hospital-wide impact of a standardized order set for the management of bacteremic severe sepsis. Crit. Care Med. 37, 819-824 (2009).
89. Raineri E, Pan A, Mondello P, Acquarolo A, Candiani A, Crema L. Role of the infectious diseases specialist consultant on the appropriateness of antimicrobial therapy prescription in an intensive care unit. Am. J. Infect. Control 36, 283-290 (2008).
90. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am. J. Respir. Crit. Care Med. 177, 498-505 (2008).
91. Rahal JJ. Antimicrobial resistance among therapeutic options against Gram-negative pathogens. Clin. Infect. Dis. 49(Suppl. 1), S4-S10 (2009).
92. Paul MP, Leibovici L. Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses. Infect. Dis. Clin. N. Am. 23, 277-293 (2009).
93. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect. Dis. 4, 519-527 (2004).
94. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. β lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. Br. Med. J. 328, 668 (2004).
95. Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. β lactam antibiotic monotherapy versus β lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst. Rev. CD003344 (2006).
96. Aarts MA, Hancock JN, Heyland D et al. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit. Care Med. 36, 108-117 (2008).
97. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob. Agents Chemother. 49, 1306-1311 (2005).
98. Tam VH, Gamez EA, Weston JS, Gerard LN, La Rocco MT, Caeiro JP. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin. Infect. Dis. 46, 862-867 (2008).
99. Badal R, Bouchillon S, Hawser S et al. Impact of different EUCAST and CLSI interpretive breakpoints on antimicrobial susceptibility of Pseudomonas aeruginosa SMART2007. Presented at: 19th European Congress of Microbiology and Infectious Diseases. Helsinki, Finland, 16-19 May 2009 (Abstract P818).
100. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America; American Thoracic Society. Consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2), S27-S72 (2007).
101. Bassetti M, Righi E, Viscoli C. Pseudomonas aeruginosa serious infections: mono or combination antimicrobial therapy. Curr. Med. Chem. 15, 517-522 (2008).
102. Morse PA, North N, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumption. Lancet Infect. Dis. 9, 617-624 (2009).
103. Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 51, 2582-2586 (2007).
104. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42, 2398-2402 (2004).
105. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38, 1700-1705 (2004).
106. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166, 2138-2144 (2006).
107. Maclayton DO, Suda KJ, Coval KA, York CB, Garey KW. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2μg/ml and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin. Ther. 28, 1208-1216 (2006).
108. Soriano A, Marco F, Martinez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46, 193-200 (2008).
109. Lodise TP, Graves J, Evans A et al. Relationship between vancomycin MIC and failure among patients with methicillin resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52, 3315-3320 (2008).
110. Howden BP, Ward PB, Charles PG et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38, 521-528 (2004).
111. Szabó J. hVISA/VISA: diagnostic and therapeutic problems. Expert Rev. Anti Infect. Ther. 7, 1-3 (2009).
112. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44, 1208-1215 (2007).
113. Price J, Atkinson S, Llewelyn M, Paul J. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin. Infect. Dis. 48, 996-997 (2009).
114. Soriano A, Martinez JA, Mensa J. Reply to Price et al. and to Pea and Viale. Clin. Infect. Dis. 49, 643-645 (2009).
115. Pea F, Viale P. Is the minimum inhibitory concentration of vancomycin an infallible predictor of the clinical outcome of Staphylococcus aureus bacteremia treated with vancomycin? Clin. Infect. Dis. 49, 642-643 (2009).
116. Pea F, Viale P. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin. Infect. Dis. 42, 1764-1771 (2006).
117. Wysocki M, Delatour F, Faurisson F et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob. Agents Chemother. 45,2460-2467 (2001).
118. Pea F, Furlanut M, Negri C et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in the critically ill patients: the Optivanco study. Antimicrob. Agents Chemother. 53, 1863-1867 (2009).
119. Roberts JA, Lipman J, Blot S, Rello J. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr. Opin. Crit. Care. 14, 390-396 (2008).
120. Rello J, Sole-Violan J, Sa-Borges M et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit. Care Med. 33, 1983-1987 (2005).
121. Rybak MJ, Lomaestro BM, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Pharmacotherapy 29, 1275-1279 (2009).
122. Rybak MJ, Lomaestro BM, Rotscahfer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis. 49, 325-327 (2009).
123. Nation RL, Li J. Colistin in the 21st Century. Curr. Opin. Infect. Dis. 22, 535-543 (2009).
124. El Solh AA, Alhajhusain A. Update on the treatment of Pseudomonas aeruginosa pneumonia. J. Antimicrob. Chemother. 64, 229-238 (2009).
125. Pea F, Viale P. Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock - does the dose matter? Crit. Care 13, 214 (2009).